Editor of Cloning & Stem Cells Journal and Editor of Genetic Engineering News Available for Media Comment.Business Editors & Health/Science Writers BIOWIRE2K LARCHMONT, N.Y.--(BW HealthWire)--Aug. 9, 2001 Ian Wilmut, Ph.D., editor in chief of the peer-reviewed journal peer-reviewed journal Refereed journal Academia A professional journal that only publishes articles subjected to a rigorous peer validity review process. Cf Throwaway journal. Cloning & Stem Cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young and John Sterling, managing editor of Genetic Engineering News (GEN), will be available for media comment on President Bush's remarks regarding stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. research this evening and the implications of his decision. Cloning & Stem Cells, edited by Ian Wilmut, Ph.D., is an authoritative peer-reviewed journal established two years ago and indexed in Index Medicus/MEDLINE. (www.liebertpub.com/clo). Dr. Wilmut, one of the world's foremost experts on cloning, is affiliated with the Roslin Institute, Midlothian, Scotland. John Sterling is the managing editor of Genetic Engineering News (GEN), the most widely read and respected biotechnology publication in the world for more than 20 years (www.genengnews.com). Both are published by Mary Ann Liebert Inc. (www.liebertpub.com) The covers of both publications will be sent electronically to members of the media on request. Cloning & Stem Cells began two years ago in response to the strong imperative for such a peer-reviewed journal expressed at the first scientific conference: Cloning: Science and Policy, which took place in Washington, D.C. and was sponsored by Mary Ann Liebert and Genetic Engineering News (GEN). The journal, published in print and online, focuses on the latest progress in mammalian cloning and stem cell research. It covers original work in cloning and allied technologies such as germ line germ line n. Cells from which gametes are derived. genetic engineering, tissue regeneration, transgenics trans·gen·ics n. (used with a sing. or pl. verb) The study of or methodology used to create transgenic animals or plants. , nuclear transfer, oocyte oocyte /oo·cyte/ (-sit) the immature female reproductive cell prior to fertilization; derived from an oogonium. It is a primary o. prior to completion of the first maturation division, and a secondary o. maturation, and molecular and cellular mechanisms regulating de-differentiation and nuclear reprogramming Reprogramming refers to erasure and remodeling of epigenetic marks, such as DNA methylation, during mammalian development[1]. After fertilization some cells of the newly formed embryo migrate to the germinal ridge and will eventually become the germ cells and embryonic stem cell Embryonic stem cells (ES cells) are stem cells derived from the inner cell mass of an early stage embryo known as a blastocyst. Human embryos reach the blastocyst stage 4-5 days post fertilization, at which time they consist of 50-150 cells. ES cells are pluripotent. research. A current issue of Cloning & Stem Cells may be viewed at www.liebertpub.com/clo. "A large part of biotechnology's future in America rests on President Bush's decision," said John Sterling, managing editor of Genetic Engineering News (GEN), which was established in 1980. "Stem cell research offers tremendous opportunities to improve human lives around the world. The United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. must take the lead in stem cell research." Published 21 times a year, GEN covers all aspects of biotechnology from applied research through commercialization. It has covered stem cell research and cloning since the early 1990s, reporting on the companies involved in cloning and stem cell endeavors. Highlights from the current issue are available at www.genengnews.com. Mary Ann Liebert is a privately held, fully integrated media company that is universally acknowledged for establishing authoritative peer-reviewed journals in cutting-edge and promising areas of science and biomedical research, including Tissue Engineering; Human Gene Therapy; and AIDS Research and Human Retroviruses. A complete list of the firm's 60 journals, books and newsletters is available at www.liebertpub.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion